Stock Movers: Oracle's Cloud Sales Disappoint, Gemini's Prediction Market Approved, Eli Lilly's Obesity Drug Shows Promise

Oracle's Cloud Sales Underperform

• 📉 Oracle's shares experienced a significant drop, falling as much as 13% before the market open.
• 💡 Despite success in the competitive cloud computing market and major customers like ByteDance and Meta, Oracle's cloud sales disappointed.
• ⚠️ Wall Street raised doubts regarding the costs and time required to build AI infrastructure at the massive scale Oracle is undertaking.
• 💰 Oracle lifted its 2026 capital expenditure outlook by $15 billion to $50 billion, with a significant portion allocated to revenue-generating equipment.

Gemini Space Station Gains Regulatory Approval

• 🚀 Gemini Space Station (GEMI) shares rallied up to 15% before the bell following regulatory news.
• 🤝 The company, co-founded by the Winklevoss twins, received approval from the Commodity Futures Trading Commission (CFTC) for its derivatives exchange application.
• 📈 This approval allows Gemini to enter the prediction markets field, enabling trading on economic, financial, political, and sports forecasts.

Eli Lilly's Obesity Drug Shows Potent Results

• 💊 Eli Lilly & Co. (LLY) saw its shares jump as much as 3% based on promising results from its next-generation obesity shot, retatrutide.
• 🎯 A late-stage study indicated that patients lost more than 23% of their body weight in 68 weeks on the highest dose.
• 🦵 The drug also showed significant benefits for conditions related to obesity, with patients experiencing a more than 62% reduction in knee pain.
• 📊 Both the weight loss and pain reduction statistics exceeded market expectations.